Insider Transactions in Q1 2023 at Poseida Therapeutics, Inc. (PSTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
SELL
Payment of exercise price or tax liability
|
Direct |
26,617
-6.64%
|
$133,085
$5.35 P/Share
|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+18.8%
|
-
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.91%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+38.45%
|
-
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.38%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+33.77%
|
-
|
|
Mar 01
2023
|
Mark J Gergen Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
269,586
+30.94%
|
-
|
|
Feb 01
2023
|
Mark J Gergen Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
31,819
-8.79%
|
$222,733
$7.0 P/Share
|
|
Feb 01
2023
|
Eric Ostertag Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11,776
-1.4%
|
$82,432
$7.0 P/Share
|